Goldman Sachs tips Cochlear share price to rise 13%

One leading broker is bullish on Cochlear's shares…

| More on:
A man sees some good news on his phone and gives a little cheer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Limited (ASX: COH) share price could be heading higher from current levels.

That's the view of analysts at Goldman Sachs, which have just reiterated their buy rating on the hearing solutions company's shares.

This follows the release of a strong full year result for FY 2022 last week.

What is Goldman saying about the Cochlear share price?

According to note out of the investment bank, Goldman has reiterated its buy rating with an improved price target of $247.00.

Based on the current Cochlear share price of $218.86, this implies potential upside of 13% for investors over the next 12 months.

Goldman was impressed with the company's performance, noting that "in a highly challenging year Cochlear delivered +17% NPAT growth to reach the upper-half of the guided range."

The good news is that the broker is expecting more of the same in FY 2023. It said:

In our view, the backdrop for this year appears relatively more favourable, and we see clear scope for COH to deliver at the upper-end of another solid guidance (+8-13% to $290-305m, with further accretion possible from the Oticon Medical transaction, which is yet to close).

What about the medium term?

The good news for the Cochlear share price is that Goldman Sachs doesn't expect the company's growth to stop in FY 2023.

Its analysts believe the company is well-placed to continue this solid form through until at least FY 2025. It explained:

Overall, our NPAT forecast of $301m is at the upper-end of the guided range $290-305m, and we forecast a +10% CAGR from FY22-25E.

And while the broker acknowledges that Cochlear's shares are not cheap at current levels, it still believes they are good value compared to historic multiples and due to its positive and uncomplicated outlook. The broker said:

Whilst valuation of 28x EV/EBITDA appears high in absolute terms, it is still only in-line with its 5-year average and modestly above its 10-yr. Looking across the other 'recovery' plays in our coverage, there is less complexity to COH's near/mid-term earnings profile, and we believe it will ultimately experience lower and/or shorter-lived margin pressure through the pandemic period than peers.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Broker Notes

Bell Potter names the best ASX 200 stocks to buy in June

The broker is feeling bullish on these names this month. Let's find out why.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Broker Notes

Bell Potter says this ASX 200 share can rise 25%

Let's see what the broker is saying about this stock.

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Man smiling at a laptop because of a rising share price.
Broker Notes

9 ASX 200 shares just upgraded to strong buy ratings

Brokers have upgraded these shares amid expectations of price growth over the next 12 months.

Read more »

Red sell button on an Apple keyboard.
Broker Notes

Sell alert! Brokers say pull the plug on these 3 ASX 200 shares

Experts say it's time to press the sell button on these ASX 200 shares. Find out why.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Broker Notes

Macquarie forecasts 40% upside for this ASX All Ords stock

Let's see which stock the broker is tipping as a buy.

Read more »

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

A smiling woman with a handful of $100 notes, indicating strong dividend payments
Broker Notes

Where to invest $10,000 in ASX 200 shares this month

Brokers think these shares could be top picks for your hard-earned money this month.

Read more »